Relationship Between Contrast Media Volume and Tube Voltage in CT for Optimal Liver Enhancement, Based on Body Weight.

NCT ID: NCT03735706

Last Updated: 2020-02-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

245 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-13

Study Completion Date

2019-06-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Computed Tomography (CT) is widely used in abdominal imaging for a variety of indications. Contrast media (CM) is used to enhance vascular structures and organ parenchyma. Attenuation of the liver makes it possible to recognize hypo- and hypervascular lesions, which are often invisible on unenhanced CT images. Lesions can only be detected in case they are large enough and the contrast with the background is high enough. Heiken et al. showed already in 1995 that a difference in Hounsfield Units (HU) of at least 50 HU is needed to be able to recognize liver lesions \[1\]. On the other hand, patients should not receive more CM than necessarily, because of possible underlying physiological effects \[2-4\]. Although there has been some controversy about this recently, there is no need to give patients more CM than needed, because of increased costs, no quality improvement and their might still be a relationship with contrast induced nephropathy (CIN) \[5\].

Recent publications suggested individualization of injection protocols that can be based on either total body weight (TBW) or lean body weight (LBW) \[6-9\]. In the investigators department an injection protocol based on TBW is currently used.

Besides the CM injection parameters, scanner parameters are of influence on the attenuation as well. Because of recent technical developments it became possible to reach a good image quality (IQ) at lower tube voltages \[10\]. When the x-ray output comes closer to the 33 keV k-edge of Iodine, attenuation increases. In short, decreasing the tube voltage increases the attenuation of iodine. Scanning at a lower tube voltage therefore gives rise to even lower CM volumes. Lastly, it would be revolutionary to accomplish a liver enhancement that is homogenous, sufficient for lesion detection and comparable between patients and in the same patients, regardless of weight and scanner settings used.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Computed Tomography (CT) is a non-invasive imaging tool, used for a great variety of indications. Contrast media (CM) is used to enhance vascular structures and organ parenchyma. The visibility of liver lesions depends mainly on the ratio between the size and the difference of the lesion to the background. A large lesion might be visible without administration of CM, whilst a smaller lesion needs the addition of CM to become visible. Additionally, CM can be useful in the characterization of liver lesions. Heiken et al. (1995) found that an attenuation of the parenchyma after CM administration of at least ∆ 50 Hounsfield units (HU) compared to an unenhanced scan (in the same patient) is necessary to recognize liver lesions. This study proposed a dosing factor of 0.521 g I/kg to be necessary to reach such attenuation at a tube voltage of 120 kV \[1\].

The parenchymal enhancement depends on patient, CT scanner and CM factors. Weight, height, cardiac output, age, gender, venous access, breath-holding, renal function and comorbidity all fall under patient factors \[8\]. Recently much research showed preferable outcomes for individualized CM injection protocols, in which the contrast bolus is adapted to patient TBW, LBW or body surface area (BSA) \[6, 7, 9, 13-15\]. In a recent feasibility study in the department of the investigators, the attenuation of the liver parenchyma was evaluated. Results showed that a body weight adapted CM injection protocol resulted in more homogeneous liver enhancement compared to a fixed CM dose (not published yet).

With recent technological developments in X-ray tube technology it became possible to use lower tube voltages. As a result making it possible to perform scans with a sufficient image quality (IQ) and a low tube voltage and therefore a lower radiation dose \[10\]. Another advantage lies in the fact that reducing the tube voltage, approaching 33 keV k-edge of iodine, results in an increase in attenuation of the iodine. The new technological developments make it possible to reduce the radiation dose and CM volume at the same time. So reducing the tube voltage, makes it also possible to reduce the CM volume.

As recommended by the supplier, it is possible to calculate the total iodine load (TIL) that can be spared with the use of lower kV settings \[16\]. A reduction of 10 kV should result in a 10% reduction in CM volume. Reducing the tube voltage from 120 to 90 kV should therefore lead to a 30% reduction in CM volume. As mentioned before it is preferred to use an individualized CM injection protocol based on TBW or LBW. For this study, this theory is adapted to the concept of TBW. The following indicates which dosing factors should be used for each kV setting, based on the recommendations mentioned in the above.

120 kV -\> 0.521 g I/kg 110 kV -\> 0.469 g I/kg 100 kV -\> 0.417 g I/kg 90 kV -\> 0.365 g I/kg 80 kV -\> 0.313 g I/kg 70 kV -\> 0.261 g I/kg

The aim of present study is to investigate if adapting the dosing factor based on TBW and therefore the CM volume to the tube voltage used, results in a more homogeneous liver enhancement. The hypothesis is to find a more homogeneous enhancement between patients and in the same patient, regardless of body composition and tube voltage used.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Radiation Contrast Media Liver Body Weight

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

randomized controlled trial with 4 study arms.
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

TRIPLE

Participants Caregivers Investigators
A computer random number generator prepares the randomization schedule in a 1:1:1:1 manner, which is balanced randomization. Stratification is performed, based on age (\< 60 and ≥ 60 years) and weight \< 75 and ≥ 75 kg). Variable block randomization will distribute patients equally over time.

The blinding and randomization process will be conducted by Clinical Trial Centre Maastricht (CTCM, www.CTCM.nl) with a randomization program (ALEA) designed for usage of different techniques.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group - 120 kV - 0.521 g I/kg

Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.

Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW and a tube voltage of 120 kV.

The intervention is the application of a standard contrast media volume and a standard tube voltage of 120 kV.

Group Type ACTIVE_COMPARATOR

Unenhanced slice

Intervention Type RADIATION

One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.

Weight

Intervention Type DIAGNOSTIC_TEST

A weighing scale is used to measure a patients body weight right before the scan.

90 kV - 0.521 g I/kg

Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.

Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW.

A radiation dose reduction from 120 to 90 kV.

The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention; contrast media volume, is unchanged compared to group 1.

Group Type EXPERIMENTAL

Radiation dose reduction

Intervention Type RADIATION

The radiation dose is is different between groups

Unenhanced slice

Intervention Type RADIATION

One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.

Weight

Intervention Type DIAGNOSTIC_TEST

A weighing scale is used to measure a patients body weight right before the scan.

100 kV - 0.417 g I/kg

Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.

Contrast media volume reduction with a dosing factor of 0.417 g I/kg of TBW. A radiation dose reduction from 120 to 100 kV compared to group 1.

The intervention is a change in tube voltage to 100 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.417 g I/kg.

Group Type EXPERIMENTAL

Radiation dose reduction

Intervention Type RADIATION

The radiation dose is is different between groups

Contrast media volume reduction

Intervention Type OTHER

Contrast media volume is different between groups

Unenhanced slice

Intervention Type RADIATION

One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.

Weight

Intervention Type DIAGNOSTIC_TEST

A weighing scale is used to measure a patients body weight right before the scan.

90 kV - 0.365 g I/kg

Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.

Contrast media volume reduction with a dosing factor of 0.365 g I/kg of TBW. A radiation dose reduction from 120 to 90 kV compared to group 1.

The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.365 g I/kg.

Group Type EXPERIMENTAL

Radiation dose reduction

Intervention Type RADIATION

The radiation dose is is different between groups

Contrast media volume reduction

Intervention Type OTHER

Contrast media volume is different between groups

Unenhanced slice

Intervention Type RADIATION

One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.

Weight

Intervention Type DIAGNOSTIC_TEST

A weighing scale is used to measure a patients body weight right before the scan.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radiation dose reduction

The radiation dose is is different between groups

Intervention Type RADIATION

Contrast media volume reduction

Contrast media volume is different between groups

Intervention Type OTHER

Unenhanced slice

One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.

Intervention Type RADIATION

Weight

A weighing scale is used to measure a patients body weight right before the scan.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients referred for abdominal CT in portal venous phase
* Patients ≥ 18 years and competent to sign an informed consent

Exclusion Criteria

* Hemodynamic instability
* Pregnancy
* Renal insufficiency (defined as Glomerular Filtration Rate (GFR) \< 30 mL/min/1,73m2 \[Odin protocol 004720\])
* Iodine allergy (Odin protocol 022199)
* Age \<18 years
* Absence of informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Maastricht University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joachim Wildberger, Professor

Role: PRINCIPAL_INVESTIGATOR

Maastricht University Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MUMC+

Maastricht, Limburg, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL66971.068.18

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study About Contrast Media
NCT05678023 RECRUITING NA